Liu Feng, Fu Sheng-Nan, Chen Yan-Zhu, Yan Ou-Ying, Tong Fei, Peng Wang-Lian, Zou Ran, Wen Min-Ni, Jiang Ling, Ma Hong-Zhi, He Qian, Liu Lin, Yang Hui, Huang Xu-Fen, Han Ya-Qian, Wang Hui, Liu Xiao-Hong
Department of Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Psychological Clinic, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Integr Cancer Ther. 2021 Jan-Dec;20:15347354211006179. doi: 10.1177/15347354211006179.
This retrospective study investigated the effects of cognitive behavioral therapy (CBT) on depression, anxiety, response rates, and adverse events in patients with locoregional advanced nasopharyngeal carcinoma (NPC).
A total of 269 patients with diagnosis of stage III-IVA NPC received either CBT plus chemoradiotherapy (CBT group, n = 136) or treatment as usual (TAU) plus chemoradiotherapy (TAU group, n = 133). Patients in the CBT group received a series of 6 CBT sessions for 6 weeks during concurrent chemoradiotherapy. Depression and anxiety were assessed using the Hospital Anxiety and Depression Scale (HADS) score at baseline, the completion of radiotherapy, and 6, 12, and 24 months after radiotherapy. Response rates and adverse events were also evaluated.
Patients in the CBT group showed significantly less depression and anxiety than patients in the TAU group after the completion of radiotherapy ( < .05). Complete response rates were 99.3% (135/136) and 92.5% (123/133) in the CBT group and TAU group with a small effect size (Phi coefficient = .171), respectively ( = .005). Compared with the TAU group, the CBT group showed a significantly lower incidence of acute adverse events and late toxic effects.
The addition of CBT to chemoradiotherapy significantly reduced depressive and anxiety symptoms. CBT combined with chemoradiotherapy is associated with improved response rates, with reduced incidence of toxic effects in patients with locoregional advanced NPC. Based on this study, we registered a randomized controlled clinical trials to better define the role of CBT in patients with locoregional advanced NPC (Registration number: ChiCTR2000034701).
本回顾性研究调查了认知行为疗法(CBT)对局部区域晚期鼻咽癌(NPC)患者的抑郁、焦虑、缓解率及不良事件的影响。
共有269例诊断为III-IVA期NPC的患者接受了CBT联合放化疗(CBT组,n = 136)或常规治疗(TAU)联合放化疗(TAU组,n = 133)。CBT组患者在同步放化疗期间接受为期6周的一系列6次CBT治疗。在基线、放疗结束时以及放疗后6、12和24个月,使用医院焦虑抑郁量表(HADS)评分评估抑郁和焦虑情况。同时评估缓解率和不良事件。
放疗结束后,CBT组患者的抑郁和焦虑程度明显低于TAU组患者(P <.05)。CBT组和TAU组的完全缓解率分别为99.3%(135/136)和92.5%(123/133),效应量较小(Phi系数 = 0.171)(P = 0.005)。与TAU组相比,CBT组急性不良事件和晚期毒性反应的发生率显著更低。
在放化疗基础上加用CBT可显著减轻抑郁和焦虑症状。CBT联合放化疗可提高缓解率,降低局部区域晚期NPC患者的毒性反应发生率。基于本研究,我们登记了一项随机对照临床试验,以更好地明确CBT在局部区域晚期NPC患者中的作用(注册号:ChiCTR2000034701)。